Androgel is an Androgen drug owned by Abbvie. It contains the active ingredient testosterone and was first authorised for market use on 29 April, 2011. The drug is available in gel, metered; transdermal, gel; transdermal dosage forms.
The generic version of Androgel is expected to become available after 12 October 2026. This is due to the expiration of the last patent owned by Abbvie on the drug, thereby opening the door for potential generic production.
Androgel is primarily used as testosterone replacement therapy in males. It treats conditions associated with a deficiency or absence of endogenous testosterone, reinforcing the role of its active ingredient, testosterone.
Androgel holds a total of 8 drug patents, none of which have yet expired. The drug's patents are linked to its usage and formulation, with all patents titled 'Testosterone Gel and Method of Use' expiring on 12 October 2026. For more information on when Androgel generic could become available, see the patent details below: